SCHEMBL315192

SCHEMBL315192

Oc1[c]nc2ccccc2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.46
ALDH1A1 P00352 5/20 0.45
KMT2A Q03164 4/20 0.45
GAA P10253 3/20 0.45
NPSR1 Q6W5P4 2/20 0.45
RAB9A P51151 1/20 0.45
ACHE P22303 1/20 0.39
KDM4E B2RXH2 3/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
MEN1 O00255 3/20 0.38
NQO2 P16083 4/20 0.37
POLB P06746 2/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
RECQL P46063 1/20 0.36
MYC P01106 1/20 0.35
MAX P61244 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11206718 0.76 ACHE (0.61) MAPTALDH1A1KMT2AGAANPSR1
SCHEMBL9480318 0.73 MAPT (0.48) MAPTALDH1A1KMT2AGAAACHE
SCHEMBL410281 0.71 MAPT (0.46) MAPTALDH1A1KMT2AGAAKDM4E
SCHEMBL558407 0.71 TDP1 (0.50) MAPTALDH1A1KMT2AGAARAB9A
SCHEMBL9479792 0.71 MAPT (0.46) MAPTALDH1A1KMT2AGAAACHE
SCHEMBL9481868 0.71 MAPT (0.46) MAPTALDH1A1KMT2AGAANPSR1
SCHEMBL6295848 0.70 ALDH1A1 (0.52) MAPTALDH1A1KMT2AGAARAB9A
SCHEMBL11620950 0.69 MAPT (0.41) MAPTALDH1A1KMT2AGAARAB9A
SCHEMBL269884 0.68 ALDH1A1 (0.46) MAPTALDH1A1KMT2AGAANPSR1
SCHEMBL578186 0.68 MAPT (0.42) MAPTALDH1A1KMT2AGAANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1558587-A1 HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES AS IMMUNOMODULATORY AGENTS Pfizer Products Inc. (US) 2005-08-03 EP claimed
US-20040097554-A1 Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents PFIZER INC 2004-05-20 US claimed
WO-2004039375-A1 METHODS OF USING CCR1 ANTAGONISTS AS IMMUNOMODULATORY AGENTS PFIZER PRODUCTS INC. (US) 2004-05-13 WO claimed
WO-2004039787-A1 HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES AS IMMUNOMODULATORY AGENTS PFIZER PRODUCTS INC. (US) 2004-05-13 WO claimed
US-20040087571-A1 Methods of using CCR1 antagonists as immunomodulatory agents PFIZER INC 2004-05-06 US claimed
US-20020198207-A1 Novel Hexanoic acid derivatives KATH JOHN CHARLES (US) 2002-12-26 US claimed
US-6403587-B1 AUTOIMMUNE DISEASES, ACUTE AND CHRONIC INFLAMMATORY CONDITIONS, ALLERGIC CONDITIONS, INFECTION ASSOCIATED WITH INFLAMMATION, VIRAL, TRANSPLANTATION TISSUE REJECTION, ATHEROSCLEROSIS, RESTENOSIS, HIV INFECTIVITY, AND PFIZER INC. 2002-06-11 US claimed
US-6302924-B1 THERMAL PRINTING BASF AKTIENGESELLSCHAFT (DE) 2001-10-16 US claimed
CN-1057772-C Compounds and compositions for treating immunomodulatory inflammation AXYS PHARMACEUTICAL CORP (US) 2000-10-25 CN claimed
EP-0966443-A1 HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR PFIZER INC. (US) 1999-12-29 EP claimed
EP-0713488-B1 [1,3,4]TRIAZOLO [1,5-AL]PYRIDINES USED AS INTERMEDIATE PRODUCTS FOR THE SYNTHESIS OF DYES BASF AG (DE) 1997-10-15 EP claimed
EP-0509302-B1 Process for transfer of methine dyes BASF AG (DE) 1997-01-29 EP claimed
US-5525623-A TRYPTASE INHIBITORS ARRIS PHARMACEUTICAL CORPORATION (US) 1996-06-11 US claimed
CN-1119019-A Compositions and methods for treating immunomodulatory inflammation ARRIS PHARM CORP (US) 1996-03-20 CN claimed
EP-0688337-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNOMEDIATED INFLAMMATORY DISORDERS ARRIS PHARMACEUTICAL CORPORATION (US) 1995-12-27 EP claimed
EP-0413226-B1 [1,2,4]Triazo [1,5-a]pyridine BASF AG (DE) 1995-05-24 EP claimed
WO-1994020527-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNOMEDIATED INFLAMMATORY DISORDERS ARRIS PHARMACEUTICAL CORPORATION (US) 1994-09-15 WO claimed
US-5256624-A Transfer of methine dyes BASF AKTIENGESELLSCHAFT (DE) 1993-10-26 US claimed
EP-0509302-A1 Process for transfer of methine dyes BASF Aktiengesellschaft (DE) 1992-10-21 EP claimed
US-5101028-A Intermediates for dyes BASF AKTIENGESELLSCHAFT (DE) 1992-03-31 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087571-A1 Methods of using CCR1 antagonists as immunomodulatory agents CCR1, CCR3, CCRL2 MAPT 4783/4885ALDH1A1 438/4885KMT2A 2266/4885
US-20020198207-A1 Novel Hexanoic acid derivatives HCAR3, HCAR1, FFAR1 MAPT 4547/4885ALDH1A1 169/4885KMT2A 2539/4885
US-20040097554-A1 Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents CCR1, HCAR1, CCR3 MAPT 4041/4885ALDH1A1 303/4885KMT2A 4284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.